September 21, 2010 – Two companies announced that they have entered into a distribution agreement in the United States. The agreement allows Vascular Solutions to distribute Shepherd Scientific’s Angio Assist and Teirstein Edge products.
September 21, 2010 – The first patients have been enrolled in a trial testing a new treatment for refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is designed to assess the clinical efficacy of the Neovasc Reducer. The goal is to minimize angina symptoms after six months.
September 21, 2010 – Ventricular assist devices (VADs) can restore normal hemodynamics and support recovery of native cardiac function after acute myocardial infarction (AMI), according to a study published in the September 2010 issue of The Annals of Thoracic Surgery. The study looked at patients who used Abiomed’s AB5000 Ventricular Assist Device.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
September 20, 2010 - Results for the first-in-human study for a robotic cath lab navigation system will be announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference. Corindus Vascular Robotics will present information on the study involving its CorPath 200 System.
September 20, 2010 – The U.S. Food and Drug Administration (FDA) has approved the Integrity coronary stent system, which is said to offer better delivery.
September 20, 2010 — McLeod Regional Medical Center in Florence, S.C., has signed a new agreement to help streamline its cardiology workflow.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
September 20, 2010 - A phase 1 porcine model study demonstrated that it is possible to successfully and repeatedly deliver a mitral valve implant.
September 20, 2010 - Interim six-month results for a stent system designed to treat bifurcation lesions will be presented during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, D.C.
September 20, 2010 – Transcatheter ventricular assist device (VAD) company Abiomed will highlight its devices at several events during the 2010 Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, Sept, 21-25, at the Washington Convention Center in Washington, D.C.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
September 20, 2010 – Patient enrollment has started in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir Medical’s novolimus-eluting coronary stent with bioabsorbable coating, the Elixir DESyne BD. The first cases were enrolled by professor Joachim Schofer from the Universitäres Herz-und Gefä?zentrum in Hamburg, Germany, and Dr. Karl E.
September 20, 2010 - A new intravascular ultrasound (IVUS) coronary imaging system integrating plaque spectroscopy to better guide therapy will be highlighted during the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting.
September 17, 2010 - The Food and Drug Administration (FDA) cleared the first device that combines an angioplasty balloon and an embolic capturing feature. Angioslide's Proteus device is presently indicated for use in the lower limbs during Percutaneous Transluminal Angioplasty (PTA) procedures.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
September 17, 2010 - An aortic valve has been successfully implanted in the acute porcine model by Transcatheter Technologies GmbH (TT) using its Trinity system. The acute in vivo study of the system has shown: • Accurate stepwise positioning of Trinity via an antegrade transapical approach.
September 17, 2010 - The Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) symposium, to be held Sept. 21- 25, will feature presentations on Xience V data.
September 17, 2010 – The U.S. Food and Drug Administration (FDA) today expanded the indication for three cardiac resynchronization therapy defibrillators (CRT-D) to all classes of heart failure patients.